Lytgobi 4 mg Tab 35 (Futibatinib Tablet) 4mg

LYTGOBI 4 mg tablets contain futibatinib, a kinase inhibitor prescribed for adults with advanced solid tumors. This oral therapy targets specific genetic pathways. Store at 15-25°C and keep out of reach of children. Not for self-administration without medical supervision.

Strength

4mg

Pack Size

35s

Storage

15-25°

Manufacturer / TM Owner

Taiho Oncology Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Futibatinib is used to treat adults with certain advanced solid tumors that have a specific genetic change called FGFR2 gene fusion or rearrangement. It works by blocking abnormal signals that help cancer cells grow. This medication is typically considered when other treatments have not been effective. Always consult a healthcare provider to determine if this therapy is appropriate.

Side Effects

Common effects may include mild nausea, fatigue, or changes in taste. Some patients report gastrointestinal discomfort or skin dryness. These effects are generally manageable and vary by individual. Regular monitoring by a healthcare professional helps address any concerns promptly.

Precautions & Warnings

Keep LYTGOBI tablets in their original packaging until use to protect from moisture. Store at room temperature away from direct light and heat. Handle with care and avoid crushing or splitting tablets unless instructed. Always follow your doctor’s guidance on safe handling and disposal.

Avoid Interactions

Futibatinib may interact with strong CYP3A inhibitors or inducers, altering its effectiveness. Grapefruit products can affect how the body processes this medication. Discuss all current medications, including over-the-counter and herbal products, with your healthcare provider before starting treatment.

Frequently Asked Questions

Futibatinib is used to treat adults with advanced solid tumors that have a specific FGFR2 gene change.

Store at 15-25°C in the original packaging to protect from moisture and light.

Do not crush, split, or chew tablets unless instructed by your healthcare provider.

Avoid grapefruit products and discuss all medications with your doctor to prevent interactions.

No, LYTGOBI requires a prescription from a licensed healthcare provider.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.